Unichem Laboratories rose 1.07% to Rs 194.15 at 14:55 IST on BSE after the company got ANDA approval from USFDA for Pramipexole Dihydrochloride Tablets.
The announcement was made after market hours on Friday, 21 December 2018.On the BSE, 19,000 shares were traded in the counter so far compared with average daily volumes of 13,000 shares in the past two weeks. The stock had hit a high of Rs 200.95 and a low of Rs 193.25 so far during the day.
Unichem Laboratories received final ANDA approval for its Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Boehringer Ingelheim Pharmaceuticals Inc.'s Mirapex tablets, 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg.
Pramipexole Dihydrochloride Tablets are indicated for the treatment of Parkinson's disease and for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Unichem Laboratories' net profit dropped 66.8% to Rs 15.21 crore on 12.74% rise in total income to Rs 278.50 crore in Q2 September 2018 over Q2 September 2017.
Unichem Laboratories is an international, integrated, speciality pharmaceutical company.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)